GDRX
GoodRx Holdings, Inc.
GDRX's fundamentals are mixed, but it looks expensive: trading at 88x earnings, above its usual 66x. Analysts expect earnings growth, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GDRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
GDRX's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GDRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $3.51 | — |
| Cheap | 35x | $1.38 | -61% |
| Fair | 65x | $2.60 | -26% |
| Current | 88x | $3.51 | — |
| Expensive | 213x | $8.51 | +142% |
Historical ranges are pointers, not guarantees.
GDRX's PE is in its fair range at 88x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GDRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
GDRX has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GDRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | +778% |
| Q2 2026 | $0.04 | -56% |
| Q1 2026 | $0.06 | -14% |
| Q4 2025 | $0.09 | +125% |
| Q3 2025 | $0.08 | +$0.11 |
| Q2 2025 | $0.09 | +$0.22 |
| Q1 2025 | $0.07 | +$0.08 |
| Q4 2024 | $0.04 | +$0.06 |
| Q3 2024 | -$0.03 | -200% |
GDRX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GDRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $200.4M | -1.3% |
| Q1 2026 | $194M | -4.4% |
| Q4 2025 | $194.8M | -1.9% |
| Q3 2025 | $196M | +0.4% |
| Q2 2025 | $203.1M | +1.2% |
| Q1 2025 | $203M | +2.6% |
| Q4 2024 | $198.6M | +1% |
| Q3 2024 | $195.3M | +8.5% |
GDRX's revenue grew through 2021 and has held roughly level since: $200M last quarter, down 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 12% | -1.4 points |
| Q1 2026 | 7.2% | -4.3 points |
| Q4 2025 | 12% | +2.5 points |
| Q3 2025 | 7.5% | -3 points |
| Q2 2025 | 13% | +3.3 points |
| Q1 2025 | 12% | +7.8 points |
| Q4 2024 | 9.2% | +19 points |
| Q3 2024 | 10% | +32 points |
GDRX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GDRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GDRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $80.5M | +64% |
| Q1 2026 | $10.7M | +15% |
| Q4 2025 | $31.6M | -29% |
| Q3 2025 | $74.3M | -14% |
| Q2 2025 | $49.2M | +421% |
| Q1 2025 | $9.3M | -78% |
| Q4 2024 | $44.6M | +188% |
| Q3 2024 | $86.5M | +44% |
GDRX's free cash flow has been positive every quarter for six years: $197M over the past year, up 4% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GDRX on cash flow, with more consistent year-over-year improvement.
GDRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +6.6M shares |
| 1 year | -2.5% | -9.1M shares |
| 3 years | -16% | -66.3M shares |
| 5 years | -19% | -80.8M shares |
| Available history | -4% | -14.5M shares |
GDRX has 348M diluted shares, down 2.5% from a year ago, with $85M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $2M |
| Q1 2026 | $12.6M |
| Q4 2025 | $9.4M |
| Q3 2025 | $61.1M |
| Q2 2025 | $46M |
| Q1 2025 | $99.9M |
| Q4 2024 | $188,000 |
| Q3 2024 | $5.4M |
GDRX spent $85M buying back its own shares over the past year, down 44% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GDRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GDRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 0.3x | Very low |
| Q3 2024 | 0.6x | Very low |
GDRX's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over GDRX on leverage, with a lower net debt burden relative to earnings.
GDRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 50.9 | Neutral |
GDRX's weekly RSI is 58 (neutral) and its Stochastic is 51 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GDRX PE vs Healthcare Sector
| Metric | GDRX | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 239% above |
| PE % | 63 | 33 | 30 pts above |
GDRX is trading at 88x earnings, a 239% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GDRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.43 | 2.3% above |
| 20 week MA | $3.36 | 4.5% above |
| 50 week MA | $2.84 | 24% above |
| 100 week MA | $3.56 | 1.4% below |
| 200 week MA | $4.98 | 30% below |
GDRX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GDRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.0 | $46.3 | -11% |
| 2021 | $46.3 | $33.6 | -28% |
| 2022 | $33.6 | $4.59 | -86% |
| 2023 | $4.59 | $6.70 | +46% |
| 2024 | $6.70 | $4.62 | -31% |
| 2025 | $4.62 | $2.75 | -40% |
| 2026 YTD | $2.75 | $3.51 | +28% |
GDRX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.